3-aza-bicyclo[4.2.0]octane | 327-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-aza-bicyclo[4.2.0]octane
• 英文别名: (1R,6R)-3-azabicyclo[4.2.0]octane；3-azabicyclo[4.2.0]octane
• CAS: 327-60-6
• 化学式: C₇H₁₃N
• mdl: MFCD13178702
• 分子量: 111.187
• InChiKey: LTQWPCFIFXGAFK-UHFFFAOYSA-N

物化性质

• 沸点：
  171.7±8.0 °C(Predicted)
• 密度：
  0.934±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,4-Cyclobutenopyridine 生成 3-aza-bicyclo[4.2.0]octane
  参考文献：
  名称：

  THUMMEL R. P.; KOHLI D. K., D1J. ORG. CHEM., 1978, 43, NO 25, 4882-4884

  摘要：

  DOI：

文献信息

• BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20190161468A1

  公开（公告）日：2019-05-30

  It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.

  本文提供了一种苯并螺环烷衍生物，以及其制备方法和用途。具体而言，本文提供了一种式（I）化合物，或其药用可接受的盐、立体异构体或溶剂化合物，以及其制备方法，并用于制备治疗疼痛药物的用途。
• FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR
  申请人：JACOBIO PHARMACEUTICALS CO., LTD.

  公开号：US20210163478A1

  公开（公告）日：2021-06-03

  A compound represented by formula I or a pharmaceutically acceptable salt thereof and a use thereof in preparing a drug for treating, stopping or preventing a disease or disorder mediated by FGFR4 activity.

  由式I表示的化合物或其药学上可接受的盐以及其在制备用于治疗、阻止或预防由FGFR4活性介导的疾病或紊乱的药物中的用途。
• 4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3441388A1

  公开（公告）日：2019-02-13

  Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof, a preparation method therefor, and a use thereof.

  提供了4,5,6-三取代吲唑衍生物，其制备方法以及在药物中的用途。具体来说，提供了式（I）化合物或药用可接受的盐、立体异构体、溶剂合物或前药，其制备方法以及在药物中的用途。
• 1,2,3,4-TETRAHYDROQUINOXALINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20220009894A1

  公开（公告）日：2022-01-13

  A 1,2,3,4-tetrahydroquinoxaline derivative having a structure as represented by formula (I), preparation method therefor and application thereof. These compounds can be widely applied to preparation of drugs for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders, and a new generation of RORγt agonist drugs is expected to be developed.

  一种具有如公式（I）所示结构的1,2,3,4-四氢喹喔啉衍生物，其制备方法及应用。这些化合物可以广泛应用于制备用于治疗一个或多个肿瘤、癌症、代谢性疾病、自身免疫疾病或紊乱的药物，预计将开发出新一代RORγt激动剂药物。
• FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：US20210130323A1

  公开（公告）日：2021-05-06

  Formylpyridine derivatives having FGFR4 inhibitory activities, a preparation method therefor and use thereof are described. In particular, the formylpyridine derivatives have a structure of formula (I), and the definition of each substituent in the formula are described in the description and claims. The series of compounds of the formula (I) have very strong inhibitory effects on FGFR4 kinases and very high selectivity, and can be widely used in the preparation of medicaments for treating cancers, particularly prostate cancer, liver cancer, pancreatic cancer, esophageal cancer, stomach cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, neuroglioblastoma or rhabdomyosarcoma, and prospectively will be further developed to become a new generation of FGFR4 inhibitors.

  描述了具有FGFR4抑制活性的甲酰吡啶衍生物，其制备方法及用途。具体来说，这些甲酰吡啶衍生物具有式（I）的结构，该式中每个取代基的定义在描述和权利要求中有所描述。式（I）的一系列化合物对FGFR4激酶具有非常强的抑制作用和非常高的选择性，并可广泛用于制备用于治疗癌症的药物，特别是前列腺癌、肝癌、胰腺癌、食道癌、胃癌、肺癌、乳腺癌、卵巢癌、结肠癌、皮肤癌、神经胶质母细胞瘤或横纹肌肉瘤，并有望进一步发展成为新一代FGFR4抑制剂。